Hemostasis and Thrombosis Research
The Hemostasis and Thrombosis Research Program has one goal: to provide cutting edge and dedicated comprehensive services for the evaluation and treatment of children with bleeding or clotting disorders in a comfortable environment. Additionally, patients with bleeding disorders are also cared for by the UNC Hemophilia and Thrombosis Center, a multi-disciplinary team, made up of physicians, nurse coordinators, social worker, geneticist, and physical therapists. For more information about the University of North Carolina’s Hemophilia and Thrombosis Center, please click here.
Conditions treated include:
- Bleeding disorders such as Hemophilia, von Willebrand Disease, Platelet Function Defects
- Rare Factor Deficiencies
- Thrombosis
- Other Coagulation and Bleeding Disorders
- Immune Thrombocytopenia Purpura
Currently Open Clinical Trails
| Diagnosis | Sponsor | Study Title with ClinicalTrails.Gov Link |
|---|---|---|
| Hemophilia A | Genentech | HAVEN-4 evaluating emicizumab/ACE910 in hemophilia A patients with or without inhibitors against factor VIII (Q4W) |
| Hemophilia A or B | Alnylam | ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX |
| Hemophilia A or B | Alnylam | ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX |
| Hemophilia B | Biogen, Swedish Orphan Biovitrum | B-Natural : The Natural History Study of Factor IX Treatment and Complications |